Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Danielle Boyle: This Consultation Is an Opportunity for The Entire ITP Community to Be Heard
Danielle Boyle/LinkedIn
Apr 13, 2026, 04:49

Danielle Boyle: This Consultation Is an Opportunity for The Entire ITP Community to Be Heard

Danielle Boyle, Founder and CEO of ITP Australia and New Zealand, reposted from ITP Australia and New Zealand on LinkedIn:

”This consultation is such an important opportunity for our entire ITP community to be heard.

Real‑world experiences – from both patients and clinicians – genuinely shape PBAC decisions, and a new 75mg dose of Eltrombopag could make a meaningful difference in day‑to‑day management.

For clinicians, your insights on dosing challenges, titration, platelet stability and treatment gaps carry real weight.

For patients and carers, your lived experience helps PBAC understand what the data alone can’t show – the impact on quality of life, access, affordability and stability.

If you’ve ever wished for more flexible dosing, smoother management or better treatment options, this is the moment to speak up.

Every submission adds strength to the collective voice.

Let’s make sure the needs of the ITP community are clearly represented.”

Quoting ITP Australia and New Zealand‘s post:

”ITP Community and Healthcare Professionals – Your Input Is Needed

A new 75mg dose of Eltrombopag is being proposed for consideration at the Pharmaceutical Benefits Advisory Committee (PBAC) meeting in July 2026.

This submission has the potential to expand treatment options for people living with ITP – but PBAC decisions are strongly influenced by real‑world experiences.

That’s where your voice matters.

For Patients and Carers

Your lived experience provides essential insight into:

  • How current dosing options impact daily life
  • Challenges with treatment access or affordability
  • The need for more flexible dosing
  • How an additional dose strength could support stability, safety or quality of life

Sharing your story — even a short one — can help shape future access to care for the entire ITP community.

For Healthcare Professionals – Your clinical perspective is equally important.

PBAC values feedback on:

  • Treatment gaps you observe in practice
  • Patient responses to current dosing
  • Situations where a 75mg option would improve management
  • Real‑world challenges with titration or platelet stability

Your insight helps PBAC understand the practical implications beyond clinical trial data.

Consumer Consultation is open until 20 May.

Submissions are welcomed from patients, carers, haematologists, nurses and allied health professionals.

Make a submission or learn more.

Your contribution – whether personal or clinical – can directly influence access to treatment on the Pharmaceutical Benefits Scheme (PBS).

Let’s ensure the ITP community is heard.”

Stay updated with Hemostasis Today.

bleeding disorders Danielle Boyle Eltrombopag Health Hematology Hemostasis Hemostasis News Hemostasis Today Immune thrombocytopenia ITP Medicine PBAC
NewsFeed